z-logo
open-access-imgOpen Access
Antiretroviral therapy-induced Leber’s hereditary optic neuropathy
Author(s) -
Anand Moodley,
Sudika Bhola,
Fierdoz Omar,
Jade Mogambery
Publication year - 2014
Publication title -
southern african journal of hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.859
H-Index - 18
eISSN - 2078-6751
pISSN - 1608-9693
DOI - 10.4102/sajhivmed.v15i2.24
Subject(s) - stavudine , optic neuropathy , medicine , leber's hereditary optic neuropathy , zidovudine , mitochondrial toxicity , lamivudine , mitochondrial disease , mitochondrial dna , asymptomatic carrier , nucleoside analogue , peripheral neuropathy , didanosine , virology , asymptomatic , human immunodeficiency virus (hiv) , virus , genetics , pathology , viral disease , optic nerve , biology , ophthalmology , nucleoside , diabetes mellitus , endocrinology , hepatitis b virus , gene

Optic neuropathy in HIV-infected patients results from the HIV infection itself, post-infectious auto-immune disease, opportunistic infections and drugs. Nucleoside reverse transcriptase inhibitors (NRTIs) such as zidovudine and stavudine have known mitochondrial toxicity and can cause mitochondrial myopathies, neuropathies, hyperlactataemia, and can induce mitochondrial genetic disorders. Individuals with the mutation for Leber’s hereditary optic neuropathy (LHON), a mitochondrial disorder, are usually asymptomatic but develop visual loss when exposed to external triggers such as smoking. We report on two HIV-infected patients with LHON mutations (m.14484T>C and m.11778G>A) who developed profound visual loss with antiretroviral therapy. We postulate that the phenotypic expression of LHON in these genetically predisposed individuals was triggered by NRTI drugs lamivudine and tenofovir when used in combination, despite their relatively weak mitochondrial toxic effects. 

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here